Cargando…

A curious case of T2-FLAIR mismatch in H3K27M mutant glioma

Diffuse midline gliomas are a rare relatively new classification of primary central nervous system tumors which include astrocytomas, oligodendrogliomas, and glioblastomas. The T2-FLAIR mismatch sign is regarded as a highly specific imaging feature of IDH-mutant, 1p/19q non-codeleted astrocytomas. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valentino, William L., Okada, Darren, Bhanu, Shiv
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218295/ https://www.ncbi.nlm.nih.gov/pubmed/35755103 http://dx.doi.org/10.1016/j.radcr.2022.05.017

Ejemplares similares

Impact of Inversion Time for FLAIR Acquisition on the T2-FLAIR Mismatch Detectability for IDH-Mutant, Non-CODEL Astrocytomas
por: Kinoshita, Manabu, et al.
Publicado: (2021)

Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas
por: Deguchi, Shoichi, et al.
Publicado: (2020)

BT-1 An autopsy case of multicentric malignant glioma, H3K27M mutant
por: Hayashi, Nobuhide, et al.
Publicado: (2021)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas
por: Abe, Hideaki, et al.
Publicado: (2020)

Prognostic Implication of Patient Age in H3K27M-Mutant Midline Gliomas
por: Vuong, Huy Gia, et al.
Publicado: (2022)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
por: ABE, Hideaki, et al.
Publicado: (2018)

NI-09 CLINICAL SIGNIFICANCE OF T2-FLAIR MISMATCH SIGN IN LOWER GRADE GLIOMAS
por: Deguchi, Shoichi, et al.
Publicado: (2019)

NI-17 T2-FLAIR MISMATCH SIGN IN DIFFUSE GLIOMA AND DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMOR
por: Onishi, Shumpei, et al.
Publicado: (2019)

Infiltrative gliomas of the thalamus in children: the role of surgery in the era of H3 K27M mutant midline gliomas
por: Dorfer, Christian, et al.
Publicado: (2020)

T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology
por: Foltyn, Martha, et al.
Publicado: (2020)

Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant
por: Banan, Rouzbeh, et al.
Publicado: (2017)

H3K27M-mutant, hemispheric diffuse glioma in an adult patient with prolonged survival
por: Chia, Noel, et al.
Publicado: (2021)

HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA
por: Kawakibi, Abed Rahman, et al.
Publicado: (2020)

Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma
por: Wingerter, Arthur, et al.
Publicado: (2021)

Developing H3K27M mutant selective radiosensitization strategies in diffuse intrinsic pontine glioma
por: Parsels, Leslie A., et al.
Publicado: (2023)

Genomic profiling and prognostic factors of H3 K27M‐mutant spinal cord diffuse glioma
por: Chai, Rui‐Chao, et al.
Publicado: (2023)

A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma
por: Peng, Youheng, et al.
Publicado: (2023)

DWI-FLAIR Mismatch at MRI Versus Infarct-Penumbra Mismatch on CT Perfusion
por: Collard, Margaux, et al.
Publicado: (2019)

K27M-mutant histone-3 as a novel target for glioma immunotherapy
por: Ochs, Katharina, et al.
Publicado: (2017)

STAT3 as a biologically relevant target in H3K27M-mutant diffuse midline glioma
por: Anderson, Jacob B., et al.
Publicado: (2023)

H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant
por: Maeda, Sachi, et al.
Publicado: (2020)

NI-10 T2/FLAIR mismatch sign and methionine PET uptake in grade II and III gliomas
por: Ebiko, Yusuke, et al.
Publicado: (2020)

Quantitative relaxometry using synthetic MRI could be better than T2-FLAIR mismatch sign for differentiation of IDH-mutant gliomas: a pilot study
por: Kikuchi, Kazufumi, et al.
Publicado: (2022)

Diffuse midline gliomas, H3 K27M-mutant are associated with less peritumoral edema and contrast enhancement in comparison to glioblastomas, H3 K27M-wildtype of midline structures
por: Banan, Rouzbeh, et al.
Publicado: (2021)

Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas
por: Welby, John P., et al.
Publicado: (2019)

Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities
por: Gojo, Johannes, et al.
Publicado: (2020)

Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults
por: Schulte, Jessica D, et al.
Publicado: (2020)

New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma
por: Argersinger, Davis P., et al.
Publicado: (2021)

A rare case of adult diffuse midline glioma with H3 K27M mutant in the prepontine cistern
por: Chen, Xueling, et al.
Publicado: (2021)

Differences in survival prognosticators between children and adults with H3K27M‐mutant diffuse midline glioma
por: Gong, Xuan, et al.
Publicado: (2023)

STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma
por: Zhang, Liang, et al.
Publicado: (2022)

The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study
por: Corell, Alba, et al.
Publicado: (2020)

The T2‐FLAIR mismatch sign as an imaging biomarker for oligodendrogliomas in dogs
por: Garcia‐Mora, Josefa, et al.
Publicado: (2023)

Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma
por: Lee, Chul-Hwan, et al.
Publicado: (2019)

H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis
por: Kleinschmidt-DeMasters, Bette K., et al.
Publicado: (2018)

HGG-50. TWO CASES OF H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA OF CERVICAL SPINAL CORD
por: Kuroha, Masae, et al.
Publicado: (2020)

Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3 K27M Mutant Diffuse Midline Glioma
por: Hohm, Annika, et al.
Publicado: (2021)

HGG-03. THE GLYCOSPHINGOLIPIDS METABOLISM IS A NOVEL TARGET IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA
por: Paret, Claudia, et al.
Publicado: (2021)

Adaptive rewiring of purine metabolism promotes treatment resistance in H3K27M-mutant diffuse midline glioma
por: Peterson, Erik R., et al.
Publicado: (2023)

BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
por: Panditharatna, Eshini, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_opppbup4611bglm27v1pf0v2ap